TY - JOUR
T1 - Development and current status of Antibody-drug conjugate (ADC)
AU - Manabe, Shino
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Antibody-drug conjugates (ADCs) are expected as next therapeutic antibodies. At present, four ADCs have been approved. ADCs consist from three components, antibody, cytotoxic agents, and linker. In this paper, recent advances of ADC developments are described. From view of antibody development, internarization ability and cancer stromal targeting therapy concept are described. For cytotoxic agents, features of representative agents including radio isotopes are described. Linker technology development for homogeneous ADC preparation is also focused. Representative bioorthogonal reaction for ADC preparation is also included.
AB - Antibody-drug conjugates (ADCs) are expected as next therapeutic antibodies. At present, four ADCs have been approved. ADCs consist from three components, antibody, cytotoxic agents, and linker. In this paper, recent advances of ADC developments are described. From view of antibody development, internarization ability and cancer stromal targeting therapy concept are described. For cytotoxic agents, features of representative agents including radio isotopes are described. Linker technology development for homogeneous ADC preparation is also focused. Representative bioorthogonal reaction for ADC preparation is also included.
KW - Antibody-drug conjugate
KW - Bioorthogonal reaction
KW - Cancer stromal targeting therapy
KW - Radioimmuno therapy
UR - http://www.scopus.com/inward/record.url?scp=85072651797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072651797&partnerID=8YFLogxK
U2 - 10.2745/dds.34.10
DO - 10.2745/dds.34.10
M3 - Article
AN - SCOPUS:85072651797
VL - 34
SP - 10
EP - 21
JO - Drug Delivery System
JF - Drug Delivery System
SN - 0913-5006
IS - 1
ER -
